Excel Industries Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/oa7nwr0jsirfcgn54991hjft.pdf

Key Takeaways


Demand & Cycle

Shroff: "So general environment is of uncertainty and a lot of volatility. So it would be difficult to give you any forward-looking guidance. Generally, we don't want to go into giving guidance, but I can only tell you that there's a lot of uncertainty on policies, etc., globally."

New Contract & Growth Initiatives


Competitive Position & Chemistry

Shroff: "We don't buy phosphorus from China, so I can at least clearly tell you that. And I don't know about what happens in the market, but I don't think China is a key determinant of the phosphorus pricing today."

Operations & Capacity


Margins & Strategy

Shroff: "Pricing is an important part of our strategy, and it goes very well hand-in-hand with making sure that we continue to be preferred suppliers."

Guidance & Commitments

CommitmentSpecificsTimeline
New supply contract revenue startSupplies begin, contributing to revenuesQ2 FY26
R&D center operationalNew corporate R&D center liveH1 FY26
Biocide capacity expansion completeCapacity doubled for existing biocide productH2 FY26
CAPEX spendRs. 200-300 crores total, ~Rs. 40-50 crores/year maintenanceOver next 3 years
EBITDA margin rangeStay in 13%-15% rangeOngoing target
Growth CAPEX asset turnover1.25x to 1.5x on future growth CAPEXSubject to product/opportunity selection

Key Metrics

MetricQ4 FY25
Revenue₹248 cr, +26% QoQ
EBITDA₹20 cr, +61% QoQ
EBITDA margin8.0%, vs 6.3% in Q3 FY25
Profit after tax₹11 cr, vs ₹6 cr in Q3 FY25
FY25 revenue₹978 cr, +18% YoY
FY25 EBITDA₹121 cr, +400% YoY
FY25 EBITDA margin12.3%, vs 2.9% in FY24
FY25 profit after tax₹84 cr, +453% YoY
Agrochemical intermediates share50%–60% of portfolio
Specialty chemicals share20%–30% of portfolio
Polymer additives share5%–8% of portfolio
Pharma intermediates and API share4%–8% of portfolio
Export share18% of overall revenue
Capacity utilization70%–75%
Target EBITDA margin range13%–15%
Planned capex over next 3 years₹200–300 cr
FY19–FY24 cumulative capex~₹346 cr
Annual maintenance and modernization capex₹40–50 cr
R&D center investment~₹15 cr
Biocide capacity expansion investment₹10.3 cr, to double capacity
Renewable electricity share48% of total requirements
Environment business share~1% of total revenues
Phosphorus-based chemistry share~80% of revenues
Top 10 products share~90% of revenues
Current asset turnover~2.5x
Target asset turnover for growth capex1.25–1.5x